SumanKambhampatiMD

PubMed

• 26 citations
  Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia
  Siddhartha Ganguly, Trisha Home, Abdulraheem Yacoub, Suman Kambhampati, Huidong Shi
  Oncotarget. 2015-09-11
• 30 citations
  Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
  Anthony R. Mato, Nilanjan Ghosh, Stephen J. Schuster, Nicole Lamanna, John M. Pagel
  Blood. 2021-05-20
• 92 citations
  Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia
  Kristie A. Blum, Anjani Advani, Louis Fernandez, Richard van der Jagt, Joseph Brandwein
  British Journal of Haematology. 2009-11-01

Abstracts/Posters

• Center Effects on Outcomes in the Treatment of Acute Myelogenous Leukemia (AML): A Multilevel, Community-Based, Case-Controlled Study
  Suman Kambhampati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Inpatient HospitalizationÍs Associated Cost and Mortality for Myeloma Patients Undergoing Autologous Stem Cell Transplant: A 13-Year Analysis of the National Inpatient...
  Suman Kambhampati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Ma...
  Suman Kambhampati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study
  Suman Kambhampati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018